Literature DB >> 9263690

Transforming growth factor-beta in human glomerular injury.

H Peters1, N A Noble, W A Border.   

Abstract

Overexpression of the cytokine transforming growth factor-beta has been identified as the key mediator of chronic progressive kidney fibrosis in experimental and human kidney diseases. The renoprotective effects of angiotensin II blockade and low-protein diets have recently been linked to downregulation of transforming growth factor-beta production. Neutralizing the actions of transforming growth factor-beta by decorin gene therapy appears to be a highly effective new approach in the treatment of renal fibrosis.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9263690     DOI： 10.1097/00041552-199707000-00014

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN： 1062-4821            Impact factor:   2.894


  10 in total

1.  Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.

Authors:  Sydney R Murphy; Annette J Dahly-Vernon; Kathryn M J Dunn; Chun Cheng Andy Chen; Steven R Ledbetter; Jan M Williams; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

2.  Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Authors:  Jan M Williams; Jin Zhang; Paula North; Steven Lacy; Michael Yakes; Annette Dahly-Vernon; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

3.  Transforming growth factor-beta1 in the urine of young children with urinary tract infection.

Authors:  Evangelia Farmaki; Fotis Papachristou; Richard M Winn; Nicolas Karatzas; John Sotiriou; Emmanuel Roilides
Journal:  Pediatr Nephrol       Date:  2004-12-15       Impact factor: 3.714

Review 4.  Kidney aging--inevitable or preventable?

Authors:  Devasmita Choudhury; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

5.  The role of urinary TGF-β₁, TNF-α, IL-6 and microalbuminuria for monitoring therapy in posterior urethral valves.

Authors:  Ankur Mandelia; Minu Bajpai; Sandeep Agarwala; Arun K Gupta; Rakesh Kumar; Abid Ali
Journal:  Pediatr Nephrol       Date:  2013-06-08       Impact factor: 3.714

6.  Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.

Authors:  Jinhua Li; Naomi Vittoria Campanale; Rong Jiao Liang; James Antony Deane; John Frederick Bertram; Sharon Denise Ricardo
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury.

Authors:  Chun Cheng Andy Chen; Aron M Geurts; Howard J Jacob; Fan Fan; Richard J Roman
Journal:  Physiol Genomics       Date:  2012-12-18       Impact factor: 3.107

8.  Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.

Authors:  Misako Sato; Yasuteru Muragaki; Shizuya Saika; Anita B Roberts; Akira Ooshima
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 9.  Pulmonary fibrosis.

Authors:  David A Zisman; Michael P Keane; John A Belperio; Robert M Strieter; Joseph P Lynch
Journal:  Methods Mol Med       Date:  2005

10.  Role of Urinary Transforming Growth Factor Beta-B1 and Monocyte Chemotactic Protein-1 as Prognostic Biomarkers in Posterior Urethral Valve.

Authors:  Pranay Panigrahi; Sarita Chowdhary; Shyamendra Pratap Sharma; Rakesh Kumar; Neeraj Agarwal; Shiv Prasad Sharma
Journal:  J Indian Assoc Pediatr Surg       Date:  2020-06-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.